BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32935597)

  • 1. Rivaroxaban for the treatment of venous thromboembolism in pediatric patients.
    Cohen O; Levy-Mendelovich S; Ageno W
    Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):733-741. PubMed ID: 32935597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
    Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
    Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
    Lee JH; Oh YM; Lee SD; Lee JS
    J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
    Vedovati MC; Giustozzi M; Becattini C
    Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
    Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Nicklaus MD; Ludwig SL; Kettle JK
    J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban for the treatment and prevention of thromboembolic disease.
    Antoniou S
    J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for prevention and treatment of venous thromboembolism.
    Chan NC; Weitz JI
    Future Cardiol; 2019 Mar; 15(2):63-77. PubMed ID: 30779598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
    Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
    Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature.
    Branstetter JW; Kiskaddon AL; King MA; Coalter C; Grubbs KM; Fly H; Male C; Brandão L; Goldenberg NA
    Semin Thromb Hemost; 2021 Sep; 47(6):643-653. PubMed ID: 33971679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies.
    Choe HK; De Sancho MT; Kim SS; Dai T; Shah MA
    Blood Coagul Fibrinolysis; 2018 Mar; 29(2):227-230. PubMed ID: 29389673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.